BioVision ANGPT1 Antibody (CT)


ALTERNATE NAMES:	ANGPT1; KIAA0003; Angiopoietin-1
CATALOG #:	6760-100
AMOUNT:	100 µl
HOST/ISOTYPE:	Rabbit IgG
IMMUNOGEN:	This ANGPT1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 374-402 amino acids from the C-terminal region of human ANGPT1.
PURIFICATION:	This antibody is purified through a protein A column, followed by peptide affinity purification.
MOLECULAR WEIGHT:	~57.51 kDa
FORM:	Liquid
FORMULATION:	Supplied in PBS with 0.09% (W/V) sodium azide.
SPECIES REACTIVITY:	Human. Predicted cross reactivity with mouse, bovine and pig samples.

STORAGE CONDITIONS: Maintain refrigerated at 2-8°C for up to 6 months. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

DESCRIPTION: Angiopoietin-1 (Ang-1) is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. And-1/ Tie-2 signaling promotes angiogenesis during the development, remodeling, and repair of the vascular system. Transgenic mice lacking expression of either Ang-1 or Tie-2 fail to develop a fully functional cardiovascular system and die before birth. Postnatally, the angiogenic activity of Ang-1/Tie-2 is required during normal tissue repair and remodeling of the female endometrium in the menstrual cycle. Ang-1/Tie-2 signaling appears to be regulated by Angiopoietin-2 (Ang-2), a natural antagonist for Tie-2 that exerts its effects through an internal autocrine loop mechanism. In addition to suppressing endothelial cell activation by inhibiting the expression of adhesion and inflammatory molecules. Ang-1 enhances endothelial cell survival and capillary morphogenesis, and lessens capillary permeability. As such, Ang-1 has a potential to become an effective therapeutic agent for treating various endothelium disorders, including several severe human pulmonary diseases. The efficacy of cell-based Ang-1 gene therapy for acute lung injury (ALI) has recently been studied in a rat model of ALI. The results of this study show that such therapy can markedly improve lung condition and suggest that Ang-1 therapy may represent a potential new strategy for the treatment and/or prevention of acute respiratory distress injury (ARDI), a significant cause of morbidity and mortality in critically ill patients. Recombinant human ANG-1, derived from HeLa cells, is a C-terminal histidine tagged glycoprotein which migrates with an apparent molecular mass of 60.0 - 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein.

Western blot: ~1:1000

APPI ICATION.



RELATED PRODUCTS:

- ANG-1, human recombinant (Cat. No. 7115-10, -50)
- Human CellExp[™] Angiopoietin-2, human recombinant (Cat. No. 7395-10, -50)
- Angiopoietin-2, mouse recombinant (Cat. No. 7555-10)
- ANG-2, human recombinant (Cat. No. 7116-10, -50)
- ANGPTL3 (human) Serum ELISA Kit (Cat. No. K4914-100)
- ANGPTL3 (mouse/rat) Serum ELISA Kit (Cat. No. K4915-100)
- ANGPTL6 (human) Serum ELISA Kit (Cat. No. K4916-100)
- Angiopoietin-1 (human) ELISA Kit (Cat. No. K7115-100)
- Angiopoietin-2 (human) ELISA Kit (Cat. No. K7116-100)

Note: This information is only intended as a guide. The optimal dilutions must be determined by the user.

FOR RESEARCH USE ONLY! Not to be used on humans.

Gentaur